Translating Scientific Breakthroughs into Promise for Patients

From discovery through commercialization, all of us at Ardelyx are driven to advance targeted therapies where significant medical needs persist. We have developed a unique and innovative platform that has enabled the discovery of new biological mechanisms and pathways to create targeted, first-in-class, oral, small molecule therapies to meet these needs. Our lead candidate, tenapanor, is currently under FDA review for the control of serum phosphorus in adult patients with chronic kidney disease on dialysis.

With Integrity and Dedication, We Make a Difference for Patients

Join Us

We are… Passionate. Fearless. Dedicated. Inclusive!

Patients & Families

Translating scientific breakthroughs into promise for patients.

For Investors

Creating value from

Recent News

May 6, 2021

Ardelyx Reports First Quarter 2021 Financial Results and Recent Business...

April 29, 2021

Ardelyx Announces Extension of the PDUFA Review Period for Tenapanor for the...

April 16, 2021

Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)